StockNews.AI
JNJ
StockNews.AI
91 days

Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

1. JNJ faces $260 million verdict over talc-based Baby Powder linked to asbestos exposure.

2m saved
Insight
Article

FAQ

Why Very Bearish?

The substantial jury verdicts against JNJ for talc-related harms could signal increased litigation costs and potential settlements, adversely affecting investor confidence. Similar past cases, like the talc litigation in 2018, had detrimental effects on JNJ's stock price.

How important is it?

The scale of the verdict and its impact on JNJ's financial standing makes it highly relevant. Legal challenges concerning consumer safety are critical for a pharmaceutical company’s reputation and stock valuation.

Why Long Term?

Ongoing legal challenges may lead to prolonged uncertainty and financial liabilities for JNJ. Past litigation cases have shown that the repercussions can last for years, impacting JNJ’s business actions and stock performance.

Related Companies

PGPFEMRK
DALLAS--(BUSINESS WIRE)--National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen. The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed wi.

Related News